April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial
Dec 28, 2024, 11:14

Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial

Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X:

“Tislelizumab gets FDA approval for Metastatic Gastric or GE junction adenocarcinoma Her2 negative with PDL1 More than 1 %. This is based upon rationale 305 trial. One more option of IO in this space where pembrolizumab and nivo are already approved irrespective of PDL1.”

Read Further.

Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.